Closing Knowledge Gaps and Building Practical Skills in HRRm Testing for Metastatic Prostate Cancer
Pfizer Inc. funds educational projects to boost practical, multidisciplinary skills in HRRm testing for metastatic prostate cancer, focusing on real-world application and improved patient care.
Funder: Pfizer Inc.
Due Dates: October 7, 2026 | October 9, 2026
Funding Amounts: Up to $100,000 per project; total budget approx. $300,000; project duration up to 12 months.
Summary: Supports educational initiatives to improve healthcare professionals' skills and multidisciplinary collaboration in HRRm testing for metastatic prostate cancer.
Key Information: Only organizations (not individuals) may apply; global (ex-US) scope with priority to Europe and Asia-Pacific.
Description
This grant opportunity from Pfizer Inc. funds independent medical education (IME) projects that address knowledge and practical skill gaps among healthcare professionals involved in Homologous Recombination Repair mutation (HRRm) testing for metastatic prostate cancer. The emphasis is on moving beyond foundational knowledge to equip multidisciplinary teams—such as oncologists, urologists, pathologists, nurses, and genetic counselors—with practical, guideline-based skills for HRRm testing throughout the patient care pathway. The program encourages comprehensive, case-based, and interactive educational interventions that bridge the gap between academic and community practice, focusing on best practices in the pre-analytical phase, specimen handling, multidisciplinary collaboration, and effective communication of testing results.
